Our findings show that energy and lipid metabolism in CDK12‐deficient CRPC work together to drive CRPC progression and provide a metabolic insight into the worse prognosis of CDK12‐deficient prostate cancer patients. The gene discussed is CDK12; the disease is Familial prostate cancer.